1. Scrip
  2. >>Leadership

GSK's Oncology R&D Chief Axel Hoos Jumps To Lead Scorpion

 
• By Jessica Merrill

Axel Hoos will become the CEO of a Boston-based cancer start-up focusing on targeted precision drugs. He talked to Scrip about the decision to leave GSK after 10 years.

Axel Hoos, CEO of Scorpion Therapeutics
Axel Hoos

GlaxoSmithKline plc's oncology R&D leader Axel Hoos is leaving the company to help build a targeted cancer drug pipeline at the Boston-based start-up Scorpion Therapeutics, Inc. as CEO. Hoos said the decision to leave the big pharma was based on a personal inflection point in his career after nearly a decade there, not the company's broader oncology strategy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.